Table I.
Reported cases of VZV reactivation after COVID-19 mRNA vaccination
| Authors | n | Vaccine type | First dose | Second dose | Time to onset (days)[range (median)] | Age (years) [range (median)] | Sex |
|---|---|---|---|---|---|---|---|
| Lee et al2 | 20 | mRNA-1273 (n = 14) and BNT162b2 (n = 6) | 15 | 5 | 2-26 (6.9) | 37-77 (56) | 10 M, 10 F |
| McMahon et al3 | 10 | mRNA-1273 (n = 5) and BNT162b2 (n = 5) | 6 | 4 | NS | NS | NS |
| Psichogion et al4 | 7 | BNT162b2 | 5 | 2 | 7-20 (9) | 51-94 (77) | 4 M, 3 F |
| Rodriguez-Jiménez et al5 | 5 | BNT162b2 | 3 | 2 | 1-16 (5.4) | 39-58 (48) | 2 M, 3 F |
| Others2, 3, 4, 5 | 9 | mRNA (not specified), mRNA-1273, and BNT162b2 | 7 | 1 | 2-14 (5) | 36-81 (49) | 3 M, 6 F |
F, Female; M, male; NS, not specified.